In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine

British Journal of Dermatology

Volumn 142, Issue 4, 2000, Pages 758-765

  Gupta, Aditya K ^d   Kohli, Y ^a,b   Li, A ^a,b   Faergemann, J ^a,c   Summerbell, R C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d NONE   (Canada)

Author keywords

Azoles; In vitro susceptibility; Itraconazole; Ketoconazole; Malassezia; Terbinafine; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG SENSITIVITY; FUNGUS GROWTH; MALASSEZIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; YEAST;

ALLYLAMINE; ANTIFUNGAL AGENTS; COLONY COUNT, MICROBIAL; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MALASSEZIA; MICROBIAL SENSITIVITY TESTS;

EID: 0034089020     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03294.x     Document Type: Article

References (45)

1. 1 Yarrow AE, Ahearn DG. Genus 7: Malassezia Baillon. In: The Yeasts, a Taxonomic Study (Kreger van Rij NJW, ed.), 3rd edn. Amsterdam: Elsevier, 1984: 882-5.
2. 2 McGinley KJ, Lantis LR, Marples RR. Microbiology of tinea versicolor. Arch Dermatol 1970; 102: 168-71.
3. 3 Bergbrant IM, Faegermann J. Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol (Stockh) 1989; 69: 332-5.
4. 4 Bergbrant IM, Johansson S, Robbins D et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16: 331-8.
5. 5 Parunovic A, Halde C. Pityrosporum orbiculare. Its possible role in the seborrheic blepharitis. Am J Ophthalmol 1967; 63: 815-20.
6. 6 Borton LK, Schwartz RA. Pityrosporum folliculitis. A common acneiform condition of middle age. Arz Med 1981; 38: 598-601.
7. 7 Kellett JK, MacDonald RH. Confluent and reticulate papillomatosis. Arch Dermatol 1985; 121: 587-8.
8. 8 Danker WM, Spector SA, Furer J et al. Malassezia fungemia in neonates and adults: complication of hyperalimentation. Rev Infect Dis 1987; 9: 743-53.
9. 9 Larocco MA, Dorenbaum A, Robinson A, Pickering LK. Recovery of Malassezia pachydermatis from eight infants in a neonatal intensive care nursery: clinical and laboratory features. Pediatr Infect Dis J 1988; 7: 398-401.
10. 10 Mickelsen RA, Viano-Paulson MC, Stevens DA et al. Clinical and microbiological features of infection with Malassezia pachydermatis in high risk infants. J Infect Dis 1988; 157: 1163-8.
11. 11 Richet HM, McNeil MM, Edwards MC et al. Cluster of Malassezia furfur pulmonary infections in a neonatal intensive care unit. J Clin Microbiol 1989; 27: 1197-200.
12. 12 Welbel SF, McNeil MM, Pramanik A et al. Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit. Pediatr Infect Dis J 1994; 13: 104-8.
13. 13 Francis P, Walsh TJ. Approaches to management of fungal infections in cancer patients. Oncol 1992; 6: 133-48.
14. 14 Samonis G, Bafaloukas D. Fungal infections in cancer patients: an escalating problem. In Vivo 1992; 6: 183-93.
15. 15 Goodman DS, Teplitz ED, Wishner A et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). J Am Acad Dermatol 1987; 17: 210-20.
16. 16 Eichstedt E. Pilzbildung in der Pityriasis versicolor. Froriep Neue Notis Natur Heilk 1846; 39: 270.
17. 17 Rivolta S. Dei Parassiti Vegetali. Turin: Giulio Speirani, 1873: 469-71.
18. 18 Malassez L. Note sur le champignon du pityriasis simple. Arch Physiol 1874; 2: 451-64.
19. 19 Bizzozero J. Über die Mikrophyten der normalen Oberhaut des Menschen. Arch Pathol Anat Physiol 1884; 98: 441-59.
20. 20 Baillon H. Traité de Botanique Médicale Cryptogramique. Paris: O.Doin, 1889: 234-9.
21. 21 Castellani A, Chalmers AJ. Manual of Tropical Medicine. London: Baillière Tindall, 1913.
22. 22 Guého E, Midgley G, Guillot J. The genus Malassezia with description of four new species. Antonie van Leeuwenhoek 1996; 69: 337-55.
23. 23 Weidman FD. Exfoliative dermatitis in the Indian rhinoceros (Rhinoceros unicornis), with description of a new species: Pityrosporum pachydermatis. In: Report of the Laboratory and Museum of Comparative Pathology of the Zoological Society of Philadelphia (Fox H, ed.). Zoological Society of Philidelphia, Philadelphia, PA, 1925: 36-44.
24. 24 Simmons RB, Guého E. A new species of Malassezia. Mycol Res 1990; 94: 1146-9.
25. 25 Cunningham AC, Leeming JP, Ingham E et al. Differentiation of three serovars of Malassezia furfur. J Appl Bacteriol 1990; 68: 439-46.
26. 26 Guillot J, Guého E. The diversity of Malassezia yeasts confirmed by rRNA sequence and nuclear DNA comparisons. Antonie van Leeuwenhoek 1995; 67: 297-314.
27. 27 Guillot J, Guého E, Lesourd M et al. Identification of Malassezia species: a practical approach. J Mycol Med 1996; 6: 103-10.
28. 28 Galigiani JN, Bartlett MS, Ghannoum MA et al. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS Doc M27A 1997; 17: 1-29.
29. 29 Faergemann J. Treatment of seborrhoeic dermatitis with bifonazole. Mycoses 1989; 32: 309-11.
30. 30 Schmidt A, Rühl-Hörster B. In vitro susceptibility of Malassezia furfur against azole compounds. Mycoses 1996; 39: 309-12.
31. 31 Van Gerven F, Odds FC. The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses 1995; 38: 389-93.
32. 32 Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzniem Forsch 1992; 42: 705-10.
33. 33 Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol 1997; 137: 764-7.
34. 34 Leeming JP, Notman FH. Improved methods for isolation and enumeration of Malassezia furfur from human skin. J Clin Microbiol 1987; 25: 2017-19.
35. 35 Midgley G. The diversity of Pityrosporum (Malassezia) yeasts in vivo and in vitro. Mycopathologia 1989; 106: 143-53.
36. 36 Hoeprich PD, Merry JM. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. J Clin Microbiol 1986; 24: 269-71.
37. 37 Hoeprich PD, Huston AC. Effect of culture media on antifungal activity of miconazole and amphotericin B methyl ester. J Infect Dis 1976; 134: 336-41.
38. 38 Swamy KHS, Sirsi M, Rao GR. Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans. Antimicrob Agents Chemother 1974; 5: 420-5.
39. 39 Faergemann J, Borgers M. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Derm Venereol (Stockh) 1990; 70; 172-6.
40. 40 Balfour JA, Faulds D. Terbinafine. A review of its pharmaco-dynamics and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84.
41. 41 Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol 1989; 14: 114-5.
42. 42 Aste N, Pau M, Pinna AL et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34: 353-7.
43. 43 Villars V. Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of the skin. J Dermatol Treat 1990; 1 (Suppl. 2): 33-8.
44. 44 Faegermann J, Zehender H, Denouel J et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol (Stockh) 1993; 73: 305-9.
45. 45 Hay RJ, Moore M. Mycology. In: Textbook of Dermatology (Champion RH, Burton JL, Burns DA, Breathnach SM, eds), 6th edn, Vol. 2. Oxford: Blackwell Science Ltd, 1998: 1277-376.